As clinical oncologists gathered in Chicago to meet at the American Society of Clinical Oncology (ASCO)’s Annual Meeting, PhRMA held a media briefing to discuss critical issues facing the future of cancer research and treatment.

Reporters heard from Stephen J. Ubl, President and CEO of PhRMA, alongside industry and patient advocacy leaders on impacts the Inflation Reduction Act (IRA) will have on the research and development (R&D) of cancer treatments. The group also shared the results of a new analysis from the Partnership for Health Analytics and Research (PHAR) on how price setting provisions in the IRA impact R&D for cancer medicines.

When:

June 2, 2023 in Chicago, IL

Speakers: